Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of the prostate doubles and the second growth phase starts at 25 years and continues throughout the lifetime. While the prostate gland enlarges in a man, it presses and pinches the urethra making the bladder wall thick. This pressure and squeeze on the urethra weaken the bladder and makes it lose the ability to empty the urine completely. Urinary retention and narrowing of the urethra can cause many problems which are associated with benign prostatic hyperplasia. Benign prostatic hyperplasia is one of the common prostate problems for men older than age 50.
Benign prostatic hyperplasia testing market is primarily driven by a few key factors such as the growing geriatric male population, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure, increasing government initiatives and availability of minimally invasive surgery as a drug replacement, faster and easy performing diagnosis test results. The market is likely to grow owing to the novel diagnostic methods which are accurate than the conventional PSA blood test for benign prostatic hyperplasia which is effective in diagnosis and is expected to fuel the growth of benign prostatic hyperplasia testing market.
Market Analysis and Insights: Global Benign Prostatic Hyperplasia Testing Market
The global Benign Prostatic Hyperplasia Testing market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Benign Prostatic Hyperplasia Testing Scope and Market Size
Benign Prostatic Hyperplasia Testing market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostatic Hyperplasia Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech
...
Benign Prostatic Hyperplasia Testing Breakdown Data by Type
Urinalysis
Prostate-Specific Antigen (PSA) Blood Test
Urodynamic Test
Cystoscopy
Benign Prostatic Hyperplasia Testing Breakdown Data by Application
Hospitals
Diagnostic Centers
Clinics
Research Institutes
Benign prostatic hyperplasia testing market is primarily driven by a few key factors such as the growing geriatric male population, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure, increasing government initiatives and availability of minimally invasive surgery as a drug replacement, faster and easy performing diagnosis test results. The market is likely to grow owing to the novel diagnostic methods which are accurate than the conventional PSA blood test for benign prostatic hyperplasia which is effective in diagnosis and is expected to fuel the growth of benign prostatic hyperplasia testing market.
Market Analysis and Insights: Global Benign Prostatic Hyperplasia Testing Market
The global Benign Prostatic Hyperplasia Testing market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Benign Prostatic Hyperplasia Testing Scope and Market Size
Benign Prostatic Hyperplasia Testing market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostatic Hyperplasia Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech
...
Benign Prostatic Hyperplasia Testing Breakdown Data by Type
Urinalysis
Prostate-Specific Antigen (PSA) Blood Test
Urodynamic Test
Cystoscopy
Benign Prostatic Hyperplasia Testing Breakdown Data by Application
Hospitals
Diagnostic Centers
Clinics
Research Institutes
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Testing Revenue
1.4 Market by Type
1.4.1 Global Benign Prostatic Hyperplasia Testing Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Urinalysis
1.4.3 Prostate-Specific Antigen (PSA) Blood Test
1.4.4 Urodynamic Test
1.4.5 Cystoscopy
1.5 Market by Application
1.5.1 Global Benign Prostatic Hyperplasia Testing Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Diagnostic Centers
1.5.4 Clinics
1.5.5 Research Institutes
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Testing Market Perspective (2015-2026)
2.2 Global Benign Prostatic Hyperplasia Testing Growth Trends by Regions
2.2.1 Benign Prostatic Hyperplasia Testing Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Benign Prostatic Hyperplasia Testing Historic Market Share by Regions (2015-2020)
2.2.3 Benign Prostatic Hyperplasia Testing Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Benign Prostatic Hyperplasia Testing Market Growth Strategy
2.3.6 Primary Interviews with Key Benign Prostatic Hyperplasia Testing Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Testing Players by Market Size
3.1.1 Global Top Benign Prostatic Hyperplasia Testing Players by Revenue (2015-2020)
3.1.2 Global Benign Prostatic Hyperplasia Testing Revenue Market Share by Players (2015-2020)
3.1.3 Global Benign Prostatic Hyperplasia Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Benign Prostatic Hyperplasia Testing Market Concentration Ratio
3.2.1 Global Benign Prostatic Hyperplasia Testing Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Testing Revenue in 2019
3.3 Benign Prostatic Hyperplasia Testing Key Players Head office and Area Served
3.4 Key Players Benign Prostatic Hyperplasia Testing Product Solution and Service
3.5 Date of Enter into Benign Prostatic Hyperplasia Testing Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Benign Prostatic Hyperplasia Testing Historic Market Size by Type (2015-2020)
4.2 Global Benign Prostatic Hyperplasia Testing Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
5.2 Global Benign Prostatic Hyperplasia Testing Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
6.2 Benign Prostatic Hyperplasia Testing Key Players in North America (2019-2020)
6.3 North America Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
6.4 North America Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
7.2 Benign Prostatic Hyperplasia Testing Key Players in Europe (2019-2020)
7.3 Europe Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
7.4 Europe Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
8 China
8.1 China Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
8.2 Benign Prostatic Hyperplasia Testing Key Players in China (2019-2020)
8.3 China Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
8.4 China Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
9 Japan
9.1 Japan Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
9.2 Benign Prostatic Hyperplasia Testing Key Players in Japan (2019-2020)
9.3 Japan Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
9.4 Japan Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
10.2 Benign Prostatic Hyperplasia Testing Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
10.4 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
11 India
11.1 India Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
11.2 Benign Prostatic Hyperplasia Testing Key Players in India (2019-2020)
11.3 India Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
11.4 India Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
12.2 Benign Prostatic Hyperplasia Testing Key Players in Central & South America (2019-2020)
12.3 Central & South America Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
12.4 Central & South America Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AEternaZentaris
13.1.1 AEternaZentaris Company Details
13.1.2 AEternaZentaris Business Overview
13.1.3 AEternaZentaris Benign Prostatic Hyperplasia Testing Introduction
13.1.4 AEternaZentaris Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020))
13.1.5 AEternaZentaris Recent Development
13.2 Astellas Pharma
13.2.1 Astellas Pharma Company Details
13.2.2 Astellas Pharma Business Overview
13.2.3 Astellas Pharma Benign Prostatic Hyperplasia Testing Introduction
13.2.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.2.5 Astellas Pharma Recent Development
13.3 Eli Lilly and Company
13.3.1 Eli Lilly and Company Company Details
13.3.2 Eli Lilly and Company Business Overview
13.3.3 Eli Lilly and Company Benign Prostatic Hyperplasia Testing Introduction
13.3.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.3.5 Eli Lilly and Company Recent Development
13.4 IntelGenx Technologies Corp
13.4.1 IntelGenx Technologies Corp Company Details
13.4.2 IntelGenx Technologies Corp Business Overview
13.4.3 IntelGenx Technologies Corp Benign Prostatic Hyperplasia Testing Introduction
13.4.4 IntelGenx Technologies Corp Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.4.5 IntelGenx Technologies Corp Recent Development
13.5 Nymox Pharmaceutical Corporation
13.5.1 Nymox Pharmaceutical Corporation Company Details
13.5.2 Nymox Pharmaceutical Corporation Business Overview
13.5.3 Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Testing Introduction
13.5.4 Nymox Pharmaceutical Corporation Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.5.5 Nymox Pharmaceutical Corporation Recent Development
13.6 Protox Therapeutics
13.6.1 Protox Therapeutics Company Details
13.6.2 Protox Therapeutics Business Overview
13.6.3 Protox Therapeutics Benign Prostatic Hyperplasia Testing Introduction
13.6.4 Protox Therapeutics Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.6.5 Protox Therapeutics Recent Development
13.7 Quest PharmaTech
13.7.1 Quest PharmaTech Company Details
13.7.2 Quest PharmaTech Business Overview
13.7.3 Quest PharmaTech Benign Prostatic Hyperplasia Testing Introduction
13.7.4 Quest PharmaTech Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.7.5 Quest PharmaTech Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Testing Revenue
1.4 Market by Type
1.4.1 Global Benign Prostatic Hyperplasia Testing Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Urinalysis
1.4.3 Prostate-Specific Antigen (PSA) Blood Test
1.4.4 Urodynamic Test
1.4.5 Cystoscopy
1.5 Market by Application
1.5.1 Global Benign Prostatic Hyperplasia Testing Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Diagnostic Centers
1.5.4 Clinics
1.5.5 Research Institutes
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Testing Market Perspective (2015-2026)
2.2 Global Benign Prostatic Hyperplasia Testing Growth Trends by Regions
2.2.1 Benign Prostatic Hyperplasia Testing Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Benign Prostatic Hyperplasia Testing Historic Market Share by Regions (2015-2020)
2.2.3 Benign Prostatic Hyperplasia Testing Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Benign Prostatic Hyperplasia Testing Market Growth Strategy
2.3.6 Primary Interviews with Key Benign Prostatic Hyperplasia Testing Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Testing Players by Market Size
3.1.1 Global Top Benign Prostatic Hyperplasia Testing Players by Revenue (2015-2020)
3.1.2 Global Benign Prostatic Hyperplasia Testing Revenue Market Share by Players (2015-2020)
3.1.3 Global Benign Prostatic Hyperplasia Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Benign Prostatic Hyperplasia Testing Market Concentration Ratio
3.2.1 Global Benign Prostatic Hyperplasia Testing Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Testing Revenue in 2019
3.3 Benign Prostatic Hyperplasia Testing Key Players Head office and Area Served
3.4 Key Players Benign Prostatic Hyperplasia Testing Product Solution and Service
3.5 Date of Enter into Benign Prostatic Hyperplasia Testing Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Benign Prostatic Hyperplasia Testing Historic Market Size by Type (2015-2020)
4.2 Global Benign Prostatic Hyperplasia Testing Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
5.2 Global Benign Prostatic Hyperplasia Testing Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
6.2 Benign Prostatic Hyperplasia Testing Key Players in North America (2019-2020)
6.3 North America Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
6.4 North America Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
7.2 Benign Prostatic Hyperplasia Testing Key Players in Europe (2019-2020)
7.3 Europe Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
7.4 Europe Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
8 China
8.1 China Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
8.2 Benign Prostatic Hyperplasia Testing Key Players in China (2019-2020)
8.3 China Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
8.4 China Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
9 Japan
9.1 Japan Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
9.2 Benign Prostatic Hyperplasia Testing Key Players in Japan (2019-2020)
9.3 Japan Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
9.4 Japan Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
10.2 Benign Prostatic Hyperplasia Testing Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
10.4 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
11 India
11.1 India Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
11.2 Benign Prostatic Hyperplasia Testing Key Players in India (2019-2020)
11.3 India Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
11.4 India Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
12.2 Benign Prostatic Hyperplasia Testing Key Players in Central & South America (2019-2020)
12.3 Central & South America Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
12.4 Central & South America Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AEternaZentaris
13.1.1 AEternaZentaris Company Details
13.1.2 AEternaZentaris Business Overview
13.1.3 AEternaZentaris Benign Prostatic Hyperplasia Testing Introduction
13.1.4 AEternaZentaris Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020))
13.1.5 AEternaZentaris Recent Development
13.2 Astellas Pharma
13.2.1 Astellas Pharma Company Details
13.2.2 Astellas Pharma Business Overview
13.2.3 Astellas Pharma Benign Prostatic Hyperplasia Testing Introduction
13.2.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.2.5 Astellas Pharma Recent Development
13.3 Eli Lilly and Company
13.3.1 Eli Lilly and Company Company Details
13.3.2 Eli Lilly and Company Business Overview
13.3.3 Eli Lilly and Company Benign Prostatic Hyperplasia Testing Introduction
13.3.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.3.5 Eli Lilly and Company Recent Development
13.4 IntelGenx Technologies Corp
13.4.1 IntelGenx Technologies Corp Company Details
13.4.2 IntelGenx Technologies Corp Business Overview
13.4.3 IntelGenx Technologies Corp Benign Prostatic Hyperplasia Testing Introduction
13.4.4 IntelGenx Technologies Corp Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.4.5 IntelGenx Technologies Corp Recent Development
13.5 Nymox Pharmaceutical Corporation
13.5.1 Nymox Pharmaceutical Corporation Company Details
13.5.2 Nymox Pharmaceutical Corporation Business Overview
13.5.3 Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Testing Introduction
13.5.4 Nymox Pharmaceutical Corporation Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.5.5 Nymox Pharmaceutical Corporation Recent Development
13.6 Protox Therapeutics
13.6.1 Protox Therapeutics Company Details
13.6.2 Protox Therapeutics Business Overview
13.6.3 Protox Therapeutics Benign Prostatic Hyperplasia Testing Introduction
13.6.4 Protox Therapeutics Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.6.5 Protox Therapeutics Recent Development
13.7 Quest PharmaTech
13.7.1 Quest PharmaTech Company Details
13.7.2 Quest PharmaTech Business Overview
13.7.3 Quest PharmaTech Benign Prostatic Hyperplasia Testing Introduction
13.7.4 Quest PharmaTech Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
13.7.5 Quest PharmaTech Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
